Studies on preclinical models of cervical cancer further implicate that ectopic VCAM-1 over-expression on tumor cell surfaces confers cervical cancer cells the ability to evade active T cell-mediated immunotherapy, supporting a view that ectopic tumor expression of VCAM-1 impairs anti-tumor immunity [12]. This evidence concerns the gene VCAM1 and cervical cancer.